Sabato discussed how research in the field will inform how to best utilize novel therapies for indolent systemic mastocytosis now that a disease-modifying therapy is available.
Vito Sabato, MBBS
Advertisement
Articles by Vito Sabato, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
2
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study
3
New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot
4
After Sickle Cell Gene Therapy, What Comes Next?
5